Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma (SARCOGYN)
Phase II Randomized Trial of Doxorubicin Plus Dacarbazine Versus Standard Doxorubicin as First-Line Therapy for Metastatic Uterine Leiomyosarcoma or t Uterine Leiomyosarcoma Recurrent After Surgical Treatment
The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Leiomyosarcoma (LMS) represents 10-20% of soft-tissue sarcomas and has a poor prognosis in advanced stages. Retrospective multicenter data suggest that the doxorubicin plus dacarbazine combination improves progression-free survival (9.2 vs. 4.8 months) and response rates (30.9% vs. 25.6%) over doxorubicin alone in the advanced disease setting; however, this has never been investigated in randomized trials. This single-center, open-label trial compares doxorubicin plus dacarbazine with doxorubicin alone as first-line systemic therapy in patients with metastatic uterine leiomyosarcoma or with disease recurrence after prior surgical treatment.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Alexander Anokhin, PhD
- Telefonnummer: +7-915-518-85-00
- E-mail: anokhinaleks@mail.ru
Studiesteder
-
-
-
Moscow, Rusland
- Rekruttering
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
-
Kontakt:
- Alexander Anokhin, PhD
- Telefonnummer: +7-915-518-85-00
- E-mail: anokhinaleks@mail.ru
-
Kontakt:
- Alexey Rumyantsev, PhD
- Telefonnummer: +7-499-324-10-87
- E-mail: a.rumyantsev@ronc.ru
-
Ledende efterforsker:
- Alexander Anokhin, PhD
-
Underforsker:
- Alexey Rumyantsev, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
- Morphologically verified uterine leiomyosarcoma
- Age 18 to 70 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Metastatic disease at diagnosis, or disease recurrence after prior surgical treatment for localized disease
- No prior systemic anticancer therapy
- No contraindications to doxorubicin and dacarbazine
- Metastatic or recurrent disease confirmed by contrast-enhanced computed tomography (CT) of the chest, abdomen and pelvis (contrast-enhanced magnetic resonance imaging (MRI) of the pelvis is allowed)
- Measurable disease on CT or MRI prior to randomization
- Consent to treatment at N.N. Blokhin National Medical Research Center of Oncology
- Consent to the proposed chemotherapy regimen
- Adequate bone marrow function: absolute neutrophil count ≥1.5×10⁹/L, platelets ≥100×10⁹/L
- Adequate liver function: bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
- Adequate cardiac function: satisfactory left ventricular systolic function
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Doxorubicin
Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Andre navne:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Andre navne:
|
|
Eksperimentel: Doxorubicin+Dacarbazine
Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Andre navne:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Andre navne:
Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
1-year progression-free survival (PFS)
Tidsramme: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS) |
Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival
Tidsramme: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
OS is defined as time from enrollment to death due to any cause |
Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
|
Objective Response Rate
Tidsramme: After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
Proportion of patients achieving complete or partial response per RECIST 1.1 |
After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
|
incidence of Adverse events
Tidsramme: During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Proportion of patients experiencing adverse events in each treatment arm |
During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer efter histologisk type
- Sarkom
- Neoplasmer, bindevæv og blødt væv
- Neoplasmer, muskelvæv
- Leiomyosarkom
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Kulbrinter
- Kulbrinter, cyklisk
- Kulhydrater
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glycosider
- Triazener
- Imidazoler
- Anthracycliner
- Naphthacenes
- Aminoglycosider
- Daunorubicin
- Doxorubicin
- Dacarbazin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 08202511001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared because the informed consent form does not provide for sharing of data outside the research team.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .